Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aarti PharmalabsNSE:AARTIPHARM -1.06%50 EV-to-EBIT is 23.15 as of Aug. 01, 2026, which is 31% above its 10-year median of 17.64. GuruFocus rates NSE:AARTIPHARM with a GF Score™ of 50/100 and a GF Value™ of ₹647.81 (Fairly Valued). The stock has 3 warning signs investors should review. Among 692 Drug Manufacturers companies, Aarti Pharmalabs ranks worse than 64.6% on this metric.
The historical rank and industry rank for Aarti Pharmalabs's EV-to-EBIT or its related term are showing as below:
NSE:AARTIPHARM'
s EV-to-EBIT Range Over the Past 10 Years
Min: 9.37 Med: 17.64 Max: 26.04
Current: 23.14
During the past 6 years, the highest EV-to-EBIT of Aarti Pharmalabs was 26.04. The lowest was 9.37. And the median was 17.64.
NSE:AARTIPHARM's EV-to-EBIT is ranked worse than 64.6% of 692
companies
in the Drug Manufacturers industry
Industry Median: 15.77
vs NSE:AARTIPHARM: 23.14
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Aarti Pharmalabs's Enterprise Value for the quarter that ended in Mar. 2026 was ₹61,112 Mil.
Aarti Pharmalabs's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,956 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aarti Pharmalabs EV-to-EBIT Related Terms
Aarti Pharmalabs EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Aarti Pharmalabs's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Pharmalabs's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aarti Pharmalabs EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aarti Pharmalabs's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Aarti Pharmalabs's EV-to-EBIT falls into.
Aarti Pharmalabs's current Enterprise Value is ₹68,416 Mil.
Aarti Pharmalabs's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,956 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aarti Pharmalabs (NSE:AARTIPHARM) has a EV-to-EBIT of 23.15 as of Aug. 01, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Aarti Pharmalabs and its competitors. This is 31% above median its historical median of 17.64. Over the past decade, Aarti Pharmalabs' EV-to-EBIT has ranged from 9.37 to 26.04. According to the industry distribution chart, Aarti Pharmalabs ranks #447 out of 692 companies in the Drug Manufacturers industry, placing it in the top 64.6%.
Is Aarti Pharmalabs' EV-to-EBIT too high?
Aarti Pharmalabs' current EV-to-EBIT of 23.15 is 31% above median its 10-year median of 17.64. Over the past 10 years, this metric has ranged from a low of 9.37 to a high of 26.04. The Drug Manufacturers industry median EV-to-EBIT is 15.77. Aarti Pharmalabs' value of 23.15 is 46.8% above this industry median. Based on the distribution chart, Aarti Pharmalabs ranks #447 out of 692 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Aarti Pharmalabs has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aarti Pharmalabs' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Aarti Pharmalabs ranks #447 out of 692 companies for EV-to-EBIT. This places Aarti Pharmalabs in the lower half of its industry. The industry median EV-to-EBIT is 15.77. Aarti Pharmalabs' value of 23.15 is 46.8% above this benchmark. Historically, Aarti Pharmalabs' own EV-to-EBIT has ranged from 9.37 to 26.04 over the past decade. While the company's 10-year median is 17.64 vs. the industry median of 15.77, Aarti Pharmalabs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.77, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aarti Pharmalabs's current EV-to-EBIT of 23.15 is 46.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Aarti Pharmalabs and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aarti Pharmalabs's current EV-to-EBIT is 23.15, which is 31% above median its own 10-year median of 17.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Pharmalabs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Pharmalabs (NSE:AARTIPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹647.81, compared to a current price of ₹667.15 — trading 3% above its estimated fair value. The current EV-to-EBIT is 23.15, which is 31% above median its 10-year median of 17.64 and 46.8% above the Drug Manufacturers industry median of 15.77. Aarti Pharmalabs' overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Aarti Pharmalabs (NSE:AARTIPHARM), the current EV-to-EBIT is 23.15 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aarti Pharmalabs (NSE:AARTIPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Aarti Pharmalabs stock appears to be overvalued.
The current stock price of ₹667.15 is trading 3% above its estimated GF Value™ of ₹647.81.
GuruFocus considers Aarti Pharmalabs to be Fairly Valued.
Key valuation signals for NSE:AARTIPHARM:
EV-to-EBIT: 23.15 (31% above median its 10-year median of 17.64)
GF Value™: ₹647.81 vs. price of ₹667.15 (3% above fair value)
Industry Position: 46.8% above the Drug Manufacturers median (#447 of 692)
No single metric tells the full story. See the NSE:AARTIPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
50GF Score
Get the complete analysis for NSE:AARTIPHARM
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AARTIPHARM has been successfully added to your 
